THERAPY DOSSIER · th-4dc93e9228be

PEGylated TP508 (rusalatide acetate) peptide, including PEG5k-TP508 and PEG30k-TP508

Biologic · TP508 (rusalatide) is a 23-amino-acid thrombin receptor (PAR-1)-derived peptide agonist promoting angiogenesis and tissue repair; no curated ChEMBL mechanism record

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: TP508 (rusalatide) is a 23-amino-acid thrombin receptor (PAR-1)-derived peptide agonist promoting angiogenesis and tissue repair; no curated ChEMBL mechanism record
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL2111105 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Rusalatide; TP-508; TP508; Chrysalin; Rusalatide acetate
Note: Not recorded

Clinical trials 1

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00131482 ↗Injury indicationPHASE2terminated

Phase 2b Study of Chrysalin (Rusalatide) in Adults With a Fractured Distal Radius

Radius Fracture

Enrolment: 274 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28097629 ↗2017Reported benefit

Radiomitigation and Tissue Repair Activity of Systemically Administered Therapeutic Peptide TP508 Is Enhanced by PEGylation.

MouseRadiationCD-1MaleSystemic injection

Model: Acute radiation injury with assessment of wound closure, aortic ring angiogenic sprouting and DNA repair

PEG5k-TP508 enhanced wound closure after irradiation and angiogenic sprouting relative to equimolar TP508 without extending circulating half-life, while PEG30k-TP508 extended plasma half-life about 19-fold and also showed enhanced biological activity. Intermediate-sized PEGylated derivatives had lo…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…